A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Last updated: May 11, 2026
Sponsor: Eli Lilly and Company
Overall Status: Active - Recruiting

Phase

1

Condition

Obesity

Weight Loss

Diabetes And Hypertension

Treatment

LY4086940

Placebo

Clinical Study ID

NCT06945419
27267
J5U-MC-YGAA
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body.

Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Have no significant body weight change for the 3 months prior to screening

Part A and Part E:

  • Are considered healthy

  • Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) atscreening

Part B:

  • Have a BMI of 27 to 45 kg/m2 at screening

Part C:

  • Have a BMI of 25 to 45 kg/m2 at screening

Part D:

  • Have type 2 diabetes

  • Have hemoglobin A1C (HbA1c) ≥6.5% and ≤10.5% at screening

  • Have a BMI of 27 to 45 kg/m2 at screening

Exclusion

Exclusion Criteria:

  • Have had an acute cardiovascular condition within the past 6 months prior toscreening

  • Have liver disease or pancreatitis

  • Have used medications for weight loss within the 3 months prior to screening

Parts A, B, C, E:

  • Have any form of diabetes

Part D:

  • Have type 1 diabetes

Study Design

Total Participants: 216
Treatment Group(s): 2
Primary Treatment: LY4086940
Phase: 1
Study Start date:
April 23, 2025
Estimated Completion Date:
July 31, 2026

Connect with a study center

  • Lilly Centre for Clinical Pharmacology

    Singapore, 138623
    Singapore

    Completed

  • Lilly Centre for Clinical Pharmacology

    Singapore 1880252, 138623
    Singapore

    Site Not Available

  • Fortrea Clinical Research Unit

    Daytona Beach, Florida 32117
    United States

    Completed

  • Clinical Pharmacology of Miami

    Miami, Florida 33172
    United States

    Active - Recruiting

  • Fortrea Clinical Research Unit

    Daytona Beach 4152872, Florida 4155751 32117
    United States

    Site Not Available

  • Clinical Pharmacology of Miami

    Miami 4164138, Florida 4155751 33172
    United States

    Site Not Available

  • CenExel iResearch, LLC

    Decatur, Georgia 30030
    United States

    Site Not Available

  • Fortrea Clinical Research Unit

    Dallas, Texas 75247
    United States

    Completed

  • Endeavor Clinical Trials

    San Antonio, Texas 78240
    United States

    Site Not Available

  • Fortrea Clinical Research Unit

    Dallas 4684888, Texas 4736286 75247
    United States

    Site Not Available

  • Endeavor Clinical Trials

    San Antonio 4726206, Texas 4736286 78240
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.